174 related articles for article (PubMed ID: 23949734)
1. The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm.
Esposito M; Fasano A; Crisci C; Dubbioso R; Iodice R; Santoro L
Neurol Sci; 2014 Mar; 35(3):397-400. PubMed ID: 23949734
[TBL] [Abstract][Full Text] [Related]
2. Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm.
Conte A; Fabbrini G; Belvisi D; Marsili L; Di Stasio F; Berardelli A
Eur J Neurol; 2010 Mar; 17(3):449-55. PubMed ID: 19968711
[TBL] [Abstract][Full Text] [Related]
3. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Lolekha P; Choolam A; Kulkantrakorn K
Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
[TBL] [Abstract][Full Text] [Related]
4. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
Cakmur R; Ozturk V; Uzunel F; Donmez B; Idiman F
J Neurol; 2002 Jan; 249(1):64-8. PubMed ID: 11954870
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
Bhidayasiri R; Cardoso F; Truong DD
Eur J Neurol; 2006 Feb; 13 Suppl 1():21-9. PubMed ID: 16417594
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of individualized botulinum neurotoxin type A injection techniques in patients with essential blepharospasm.
Sung Y; Nam SM; Lew H
Korean J Ophthalmol; 2015 Apr; 29(2):115-20. PubMed ID: 25829828
[TBL] [Abstract][Full Text] [Related]
7. The long-term response to botulinum toxin injections in patients with blepharospasm undergoing upper eyelid surgery.
Trinchillo A; Cuomo N; Habetswallner F; Esposito M
Parkinsonism Relat Disord; 2024 Feb; 119():105958. PubMed ID: 38118281
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of focal dystonia with botulinum toxin A].
Sojer M; Wissel J; Müller J; Poewe W
Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
[TBL] [Abstract][Full Text] [Related]
9. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects.
Mitsikostas DD; Dekundy A; Hanschmann A; Althaus M; Scheschonka A; Pagan F; Jankovic J
Curr Med Res Opin; 2021 Oct; 37(10):1761-1768. PubMed ID: 34384301
[TBL] [Abstract][Full Text] [Related]
10. Apraxia of eyelid opening: clinical features and therapy.
Kerty E; Eidal K
Eur J Ophthalmol; 2006; 16(2):204-8. PubMed ID: 16703535
[TBL] [Abstract][Full Text] [Related]
11. Pretarsal application of botulinum toxin for treatment of blepharospasm.
Aramideh M; Ongerboer de Visser BW; Brans JW; Koelman JH; Speelman JD
J Neurol Neurosurg Psychiatry; 1995 Sep; 59(3):309-11. PubMed ID: 7673963
[TBL] [Abstract][Full Text] [Related]
12. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
Saad J; Gourdeau A
J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
[TBL] [Abstract][Full Text] [Related]
13. Results of botulinum toxin: an application to blepharospasm Schwartz-Jampel syndrome.
Vargel I; Canter HI; Topaloglu H; Erk Y
J Craniofac Surg; 2006 Jul; 17(4):656-60. PubMed ID: 16877909
[TBL] [Abstract][Full Text] [Related]
14. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
Park DI; Shin HM; Lee SY; Lew H
Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
[TBL] [Abstract][Full Text] [Related]
15. Primary blepharospasm: diagnosis and management.
Defazio G; Livrea P
Drugs; 2004; 64(3):237-44. PubMed ID: 14871168
[TBL] [Abstract][Full Text] [Related]
16. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.
Fezza J; Burns J; Woodward J; Truong D; Hedges T; Verma A
J Neurol Sci; 2016 Aug; 367():56-62. PubMed ID: 27423565
[TBL] [Abstract][Full Text] [Related]
17. Pretarsal blepharospasm: Clinical and electromyographic characteristics.
Grandas F; Traba A; Perez-Sanchez JR; Esteban A
Clin Neurophysiol; 2020 Jul; 131(7):1678-1685. PubMed ID: 32280019
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm.
Wabbels B; Reichel G; Fulford-Smith A; Wright N; Roggenkämper P
J Neural Transm (Vienna); 2011 Feb; 118(2):233-9. PubMed ID: 21161715
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin physiology in focal hand and cranial dystonia.
Karp BI
Toxins (Basel); 2012 Nov; 4(11):1404-14. PubMed ID: 23202323
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin type A therapy for blepharospasm.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004900. PubMed ID: 15674969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
